Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.79 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.79 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.79 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.79 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.77 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.74 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.74 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.74 |
| ▸ | GPR183 | P32249 | 1/20 | 0.74 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.74 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.64 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15868568 | 1.00 | S1PR1 (0.79) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| Fingolimod SCHEMBL15515724 | 0.90 | S1PR1 (0.85) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL14801617 | 0.88 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL6130113 | 0.88 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL17083799 | 0.88 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL29518569 | 0.87 | ENPP2 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| Phosphoric Acid SCHEMBL6507536 | 0.86 | S1PR1 (0.78) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL3390328 | 0.85 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL3392313 | 0.85 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| Fingolimod SCHEMBL7445 | 0.85 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | AC BIOSCIENCE (CH) | 2023-12-26 | — | — | US | disclosed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | disclosed |
| CN-111432815-A | Enhancing cancer treatment efficacy via sphingosine-1-phosphate pathway | AC生物科学公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3668506-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BioScience (CH) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | disclosed |
| EP-3443986-A1 | ENHANCEMENT OF CHEMOTHERAPY EFFICIENCY BY SPHINGOSINE-1-PHOSPHATE | AC BioScience (CH) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | SPHK1, S1PR1, S1PR2 | S1PR1 2/4885S1PR3 6/4885S1PR4 5/4885 |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | SPHK1, S1PR1, S1PR2 | S1PR1 2/4885S1PR3 6/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.